Injection of 99mTc-nanocolloid and ICG to Identify, Retrieve and Qualify TDLN in Early-stage NSCLC

• Status: Not yet recruiting
• Trial end date: 2024-10-10
• Target enrollment: 0
• Participant gender: All

Summary

The patient wil receive intra- or peritumoral injections of 99mTc-nanocolloid if malignancy is found during a navigation bronchoscopy. A SPECT/CT-scan will be made to image injections sites and sentinel lymph nodes (SLN). If surgery takes place to treat the lung cancer, ICG will be injected and fluorescent lymph nodes will be extensively assessed by a pathologist.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University Medical Center
• Collaborators: Johnson & Johnson; Philips Healthcare

Criteria

Inclusion Criteria:

• ASA physical status 1-3;

• Lung lesion between 1 and 5 cm;

• Imaging-based disease free lymph nodes (N0);

• Patient is deemed a candidate for definitive lung tissue resection by a thoracic surgeon.

Exclusion Criteria:

• Pregnancy;

• Inability to consent;

• Known or suspected allergy to 99mTc-nanocolloid or ICG.